Related references
Note: Only part of the references are listed.Molecular characterization of cancers with NTRK gene fusions
Zoran Gatalica et al.
MODERN PATHOLOGY (2019)
Genomic subtyping and therapeutic targeting of acute erythroleukemia
Ilaria Iacobucci et al.
NATURE GENETICS (2019)
The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells
Tamilla Nechiporuk et al.
CANCER DISCOVERY (2019)
Neurotrophic tropomyosin or tyrosine receptor kinase (NTRK) genes
Runjan Chetty
JOURNAL OF CLINICAL PATHOLOGY (2019)
Larotrectinib OK'd for Cancers with TRK Fusions
Elie Dolgin
CANCER DISCOVERY (2019)
Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3-Positive Acute Myeloid Leukemia
Kristen M. Smith et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Infantile NTRK-associated Mesenchymal Tumors
Jessica L. Davis et al.
PEDIATRIC AND DEVELOPMENTAL PATHOLOGY (2018)
A new ETV6-NTRK3 cell line model reveals MALAT1 as a novel therapeutic target - a short report
Suning Chen et al.
CELLULAR ONCOLOGY (2018)
Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins
Ed S. Kheder et al.
CLINICAL CANCER RESEARCH (2018)
Acute myeloid leukemia carrying ETV6 mutations: biologic and clinical features
Fang Zhou et al.
HEMATOLOGY (2018)
Insulin-like growth factor 1 receptor stabilizes the ETV6-NTRK3 chimeric oncoprotein by blocking its KPC1/Rnf123-mediated proteasomal degradation
Cristina E. Tognon et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Dramatic bone remodeling following larotrectinib administration for bone metastasis in a patient with TRK fusion congenital mesoblastic nephroma
Hadeel Halalsheh et al.
PEDIATRIC BLOOD & CANCER (2018)
Larotrectinib Has Antitumor Activity in TRK + Pediatric Solid Tumors
Cancer Discovery (2018)
Characterization of TRKA signaling in acute myeloid leukemia
Shelley M. Herbrich et al.
Oncotarget (2018)
Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors
Bruce W. Konicek et al.
Oncotarget (2018)
Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies
Justin Taylor et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibit ROS1/TRK/ALK Solvent-Front Mutations
Alexander Drilon et al.
CANCER DISCOVERY (2018)
NTRK fusion-positive cancers and TRK inhibitor therapy
Emiliano Cocco et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Comprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors
Darren S. Sigal et al.
Oncotarget (2018)
Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics
Ryosuke Okamura et al.
JCO PRECISION ONCOLOGY (2018)
High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults
Kathryn G. Roberts et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers
Miho J. Fuse et al.
MOLECULAR CANCER THERAPEUTICS (2017)
FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions
Maria Larrosa-Garcia et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance
Alison M. Schram et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
Alexander Drilon et al.
CANCER DISCOVERY (2017)
A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors
Alexander Drilon et al.
CANCER DISCOVERY (2017)
Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer
Mariangela Russo et al.
CANCER DISCOVERY (2016)
Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms
Eli L. Diamond et al.
CANCER DISCOVERY (2016)
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)
A. Drilon et al.
ANNALS OF ONCOLOGY (2016)
Genome-Wide Single-Nucleotide Polymorphism Array Analysis Improves Prognostication of Acute Lymphoblastic Leukemia/Lymphoma
Yunhong Wang et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2016)
Infantile Fibrosarcoma With NTRK3-ETV6 Fusion Successfully Treated With the Tropomyosin-Related Kinase Inhibitor LOXO-101
Ramamoorthy Nagasubramanian et al.
PEDIATRIC BLOOD & CANCER (2016)
NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
Alessio Amatu et al.
ESMO OPEN (2016)
Detecting and targetting oncogenic fusion proteins in the genomic era
Monika A. Davare et al.
BIOLOGY OF THE CELL (2015)
Entrectinib: a potent new TRK, ROS1, and ALK inhibitor
Christian Rolfo et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2015)
Comprehensive genomic profiling identifies a novel TNKS2-PDGFRA fusion that defines a myeloid neoplasm with eosinophilia that responded dramatically to imatinib therapy
Z. R. Chalmers et al.
BLOOD CANCER JOURNAL (2015)
TRKing Down an Old Oncogene in a New Era of Targeted Therapy
Aria Vaishnavi et al.
CANCER DISCOVERY (2015)
Activation of TRKB receptor in murine hematopoietic stem/progenitor cells induced mastocytosis
Min Yang et al.
BLOOD (2014)
ETV6-NTRK3 Is a Common Chromosomal Rearrangement in Radiation-Associated Thyroid Cancer
Rebecca J. Leeman-Neill et al.
CANCER (2014)
The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition
Elena Ardini et al.
MOLECULAR ONCOLOGY (2014)
The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma
Gang Wu et al.
NATURE GENETICS (2014)
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
K. G. Roberts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Increased circulating levels of neurotrophins and elevated expression of their high-affinity receptors on skin and gut mast cells in mastocytosis
Wen-Ming Peng et al.
BLOOD (2013)
Utility of mammaglobin immunohistochemistry as a proxy marker for the ETV6-NTRK3 translocation in the diagnosis of salivary mammary analogue secretory carcinoma
Justin A. Bishop et al.
HUMAN PATHOLOGY (2013)
Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells
Mikko Taipale et al.
NATURE BIOTECHNOLOGY (2013)
The integrated landscape of driver genomic alterations in glioblastoma
Veronique Frattini et al.
NATURE GENETICS (2013)
Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer
Aria Vaishnavi et al.
NATURE MEDICINE (2013)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia
Tea Pemovska et al.
CANCER DISCOVERY (2013)
ETV6-NTRK3 as a therapeutic target of small molecule inhibitor PKC412
Hoang Thanh Chi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
ETV6 fusion genes in hematological malignancies: A review
Etienne De Braekeleer et al.
LEUKEMIA RESEARCH (2012)
Adjuvant treatment of GIST: patient selection and treatment strategies
Heikki Joensuu
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
ETV6-NTRK3-Mediated Breast Epithelial Cell Transformation Is Blocked by Targeting the IGF1R Signaling Pathway
Cristina E. Tognon et al.
CANCER RESEARCH (2011)
Targeting the BCR-ABL Signaling Pathway in Therapy-Resistant Philadelphia Chromosome-Positive Leukemia
Thomas O'Hare et al.
CLINICAL CANCER RESEARCH (2011)
Characterization of a newly identified ETV6-NTRK3 fusion transcript in acute myeloid leukemia
Johanna M. Kralik et al.
DIAGNOSTIC PATHOLOGY (2011)
Chronic eosinophilic leukaemia with ETV6-NTRK3 fusion transcript in an elderly patient affected with pancreatic carcinoma
Fabio Forghieri et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2011)
Role of Tyrosine Kinase Inhibitors in the Management of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Michael S. Mathisen et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2011)
Imatinib Mesylate in Advanced Dermatofibrosarcoma Protuberans: Pooled Analysis of Two Phase II Clinical Trials
Piotr Rutkowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Rearrangements of NTRK1 gene in papillary thyroid carcinoma
A. Greco et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2010)
High-affinity neurotrophin receptors and ligands promote leukemogenesis
Zhixiong Li et al.
BLOOD (2009)
Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway
Kenneth Thress et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Perspectives on the development of imatinib and the future of cancer research
Brian J. Druker
NATURE MEDICINE (2009)
Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia
Michael H. Tomasson et al.
BLOOD (2008)
Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing
Peter J. Campbell et al.
NATURE GENETICS (2008)
Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia
Jane F. Apperley
LANCET ONCOLOGY (2007)
Remarkable leukemogenic potency and quality of a constitutively active neurotrophin receptor, ΔTrkA
J. Meyer et al.
LEUKEMIA (2007)
Neurotrophin/Trk receptor signaling mediates C/EBPα, -β and NeuroD recruitment to immediate-early gene promoters in neuronal cells and requires C/EBPs to induce immediate-early gene transcription
Anna Maria Calella et al.
NEURAL DEVELOPMENT (2007)
Phosphoproteomic analysis identifies the M0-91 cell line as a cellular model for the study of TEL-TRKC fusion-associated leukemia
T-L Gu et al.
LEUKEMIA (2007)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population
Ewa Brzezianska et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2006)
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants
T O'Hare et al.
CANCER RESEARCH (2005)
Angiogenic effects of BDNF examined
[Anonymous]
MOLECULAR THERAPY (2005)
AML1-ETO fusion protein up-regulates TRKA mRNA expression in human CD34+ cells, allowing nerve growth factor-induced expansion
JC Mulloy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia
R Ren
NATURE REVIEWS CANCER (2005)
Neurotrophins promote revascularization by local recruitment of TrkB+ endothelial cells and systemic mobilization of hematopoietic progenitors
P Kermani et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Directing oncogenic fusion genes into stem cells via an SCL enhancer
M Eguchi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Imatinib (STI571) resistance in chronic myelogenous leukemia: Molecular basis of the underlying mechanisms and potential strategies for treatment
SW Cowan-Jacob et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2004)
Mutations in the SAM domain of the ETV6-NTRK3 chimeric tyrosine kinase block polymerization and transformation activity
CE Tognon et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
TrkA alternative splicing: A regulated tumor-promoting switch in human neuroblastoma
A Tacconelli et al.
CANCER CELL (2004)
Neurotrophins and the immune system
JA Vega et al.
JOURNAL OF ANATOMY (2003)
Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma
C Tognon et al.
CANCER CELL (2002)
Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412
E Weisberg et al.
CANCER CELL (2002)
Brief report -: Absence of t(12;15) associated ETV6-NTRK3 fusion transcripts in pediatric acute leukemias
AJ Alessandri et al.
MEDICAL AND PEDIATRIC ONCOLOGY (2001)
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
A novel mutation within the extracellular domain of TrkA causes constitutive receptor activation
JC Arevalo et al.
ONCOGENE (2001)
Identification and characterization of an activating TrkA deletion mutation in acute myeloid leukemia
GW Reuther et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
TrkA immunoglobulin-like ligand binding domains inhibit spontaneous activation of the receptor
JC Arevalo et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
Signal transduction and transforming properties of the TEL-TRKC fusions associated with t(12;15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia
Q Liu et al.
EMBO JOURNAL (2000)
The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells
DH Wai et al.
ONCOGENE (2000)
Share Paper
